Kinnate Biopharma Inc. stock is up 5.53% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 3 March’s closed higher than February. 0% of analysts rate it a buy.
Kinnate Biopharma focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!